- Home
- RFAM vs MNOV Comparison
RFAM vs MNOV Comparison
Compare RFAM & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFAM | MNOV |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 137.8M |
| IPO Year | 2025 | 2004 |
Fundamental Metrics
Financial Performance| Metric | RFAM | MNOV |
|---|---|---|
| Price | $10.00 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 12.5K | ★ 57.5K |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $9.77 | $1.22 |
| 52 Week High | $10.02 | $3.90 |
Technical Indicators
Market Signals| Indicator | RFAM | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 42.72 |
| Support Level | $9.77 | $1.28 |
| Resistance Level | $10.02 | $1.54 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 66.67 | 51.25 |
Price Performance
Historical ComparisonAbout RFAM RF Acquisition Corp III Ordinary Shares
RF Acquisition Corp III is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.